FIGURE 4.

Olanzapine treatment caused dyslipidemia in a rodent model while vitamin D₃ supplements attenuated the worsening of the condition. (A) C57BL/6J mice were fed for 1 week with the medium-fat diet (containing 1.37 IU of cholecalciferol/g of chow) or cholecalciferol-supplemented medium-fat diet (containing 200 IU of cholecalciferol/g of chow). Each group of mice were divided into two groups and orally given 10 mg/kg/day of olanzapine or vehicle for 5 days; resulting 4 groups of mice (each n = 10) received normal chow and vehicle as control (C), normal chow and olanzapine (O), vitamin D₃-supplemented chow and vehicle (D), and vitamin D₃-supplemented chow and olanzapine (DO). Blood samples were collected from these mice 1 day after the last dose of olanzapine without fasting. (B) the triglycerides, (C) total cholesterol levels, (D) LDL cholesterol levels, and (E) HDL cholesterol levels were measured. Data are shown as means ± SEM. The multiple comparisons of olanzapine and cholecalciferol influences were compared by two-way analysis of variance (ANOVA) with post hoc Tukey’s multiple comparison test. *p < 0.05, **p < 0.01.